The backers were not disclosed.
The company intends to use the funds to conduct the final phase of its FDA clinical trials in January, 2016.
InnFocus develops the InnFocus MicroShunt® (IMS) glaucoma drainage system to treat early, moderate, and late stage primary open angle glaucoma (POAG).
The MicroShunt, which was developed in collaboration with the University of Miami’s Miller School of Medicine, Bascom Palmer Eye Institute, provides a minimally invasive procedure for shunting aqueous humor from the anterior chamber to the same “gold standard” drainage path used in trabeculectomy.
The device is made from SIBS, a biocompatible material that has been implanted in the body for over 15 years.
FinSMEs
23/12/2015